Background: Evidence suggests that "glucose effectiveness," (SG) or the effect of glucose per se to enhance net glucose disposal, may be at least as important as the insulin sensitivity index (SI) in the assessment of glucose tolerance. Our objective was to study the relationship of SG and SI parameters to left ventricular mass in a group of untreated, nondiabetic, and nonobese subjects recently diagnosed with stage I or high-normal blood pressure (BP). Methods: In this sample of subjects, among whom the expected prevalence of insulin resistance is low, we assessed SG and SI parameters using the intravenous glucose tolerance test and minimal model analysis. We also measured left ventricular mass (LVM) index and diastolic function by echocardiography. Results: We observed a strong relationship between SG and LVM index (r ϭ Ϫ0.61, P Ͻ .0001). Patients with left
T he development of left ventricular hypertrophy (LVH) in essential hypertension seems to depend on both hemodynamic and nonhemodynamic factors. 1, 2 In this respect, positive correlations between insulin resistance or plasma insulin levels and blood pressure (BP) have been reported. 3 Nonetheless, among the Pimas, a population known to have a high prevalence of insulin resistance, no correlation between insulin resistance and BP has been found. 4 Moreover, there is a lack of hypertension and LVH, despite profound insulin resistance, in the polycystic ovary syndrome. 5 Therefore, many of the mechanisms involved in the relationship among insulin resistance, high BP, and cardiac hypertrophy remain elusive.
The assessment of insulin resistance is also controversial. The clamp-based techniques 6 are excellent methods for quantifying insulin resistance. However, they are laborious and could establish a nonphysiologic situation that often tends to overestimate insulin sensitivity. 7 The intravenous glucose tolerance test (IVGTT) and minimal model is an alternative tool for the study of insulin resistance. This mathematical model provides measurement of insulin sensitivity (SI) index, which correlates well with clamp-based SI parameter. 8 Moreover, the minimal model provides measures of another parameter, namely, glucose effectiveness (SG), which represents the ability of glucose per se to effect its own disappearance from plasma independent of dynamic changes from basal insulin. This action may involve the autoregulatory effect of hepatic glucose output 9 or enhanced peripheral glucose use. 10 Evidence suggests that SG may be at least as important as SI in the assessment of glucose tolerance. 11 To date, the relationship between this parameter (glucose effectiveness) and left ventricular mass (LVM) in essential hypertension has not been studied.
Our aim in this study was to examine the relationship of LVM and diastolic function with SG and SI parameters of the IVGTT. To minimize the influence of BP and body mass index on LVM, we have studied a group of nonobese subjects with stage I or high-normal BP. Our hypothesis was that even in nonobese subjects with early stages of hypertension, parameters measuring insulin or glucose tolerance might independently influence LVM or diastolic function.
Methods

Subjects
The subjects studied were a consecutive sample of hypertensive patients (between 20 and 65 years of age) who attended our outpatient clinic, met the study criteria, and agreed to participate in the protocol. We studied 36 nondiabetic and nonobese hypertensive patients (15 men and 21 women). Obesity was defined according to the criteria used in the National Health and Nutrition Surveys (body mass index Ͼ27.8 kg/m 2 for men and Ͼ27.3 kg/m 2 for women). 12 All subjects had normal fasting glucose according to the diagnostic criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 13 Before inclusion in the study an oral glucose tolerance test was performed to exclude subjects with glucose intolerance. None of the subjects was a trained athlete and there was no ethnic heterogeneity among patients (all were white). All of the subjects had been recently diagnosed (Ͻ6 months) with essential hypertension, stage I or highnormal BP, according to the sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
14 Hypertension was established by measuring BP three times with the subject in a seated position after having relaxed 5 min in a supine position. Stage of hypertension was confirmed according to the criteria of Moore et al 15 using an ambulatory BP record. None of the patients had ever received any antihypertensive treatment. Causes of secondary hypertension were excluded. Patients with chronic atrial fibrillation or any cardiac disease other than hypertensive cardiomyopathy were also excluded. The characteristics of the studied patients are listed in Table 1 .
The procedures followed in this study were in accordance with institutional guidelines. All subjects gave informed consent and our local Ethical Committee approved the study protocol. All the procedures described in the following sections were performed during the same week.
Ambulatory BP Monitoring
Ambulatory BP (ABP) monitoring was performed using the Spacelabs 90207 device (Spacelabs, Redmond, WA). The values registration started at 9 AM and lasted for 24 h, with BP measured every 20 min. To characterize the pattern of awake and nocturnal BP, subjects recorded in a diary the time at which they went to sleep and awoke.
The following parameters were assessed: 24-h mean systolic and diastolic BP; mean diastolic and systolic BP during daytime and nighttime periods; and percentage of abnormal systolic (Ͼ135 mm Hg) or diastolic (Ͼ85 mm Hg) BP readings. Based on nocturnal BP patients were characterized as "dippers" (normal) if their sleep pressure was at least 10% lower than their awake BP or as "nondippers" (abnormal) if sleep pressure was Ͻ10% lower than awake BP.
16
IVGTT and Minimal Model Analysis
The subjects attended in the clinic after a 12-h overnight fast. On this day it was confirmed that the subjects had documented stable weight for at least 3 months and that they had consumed at least 300 g/day of carbohydrate for 3 days before the study. A catheter was inserted into an antecubital vein for blood sampling and into a contralateral antecubital vein for glucose and insulin injection. Basal samples were drawn at Ϫ10 min and Ϫ1 min. At time 0, glucose 300 mg/kg was injected in 1 min and then additional samples were collected at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 20, 22, 24, 25, 27, 30, 40, 50, 60, 70, 90 , 100, 120, 140, 160, and 180 min. An additional infusion of insulin (0.03 U/kg) was injected at time 20. The plasma glucose was measured in duplicate using a Hitachi 737 autoanalyzer (Hitachi, Tokyo, Japan) with a glucose oxidase method. Plasma insulin was measured by radioimmunoassay using a commercial kit (ICN Pharmaceutical, Horsham, PA). Both SI and SG were estimated by the minimal model approach. 17 Briefly, the model equations are:
where G(t) is the plasma glucose concentration; I(t) is the plasma insulin concentration; G(b) and I(b) are baseline glucose and insulin concentration; p1, p2, and p3 are model parameters; and X(t) is the time course of peripheral insulin effects (in minutes). Parameter p1 represents the effect of glucose per se to enhance net glucose disposal, and is known as glucose effectiveness (SG). The ratio p3/p2 define the SI index, which represents the increase in the net glucose disappearance rate, which in turn depends on the increase in insulin above basal. The SG consist of a non-insulin-dependent and a basal insulin component. This basal insulin component is calculated as the product of I(b) and SI. Therefore, the contribution of the non-insulin-dependent component (known as glucose effectiveness at zero insulin [GEZI] ) is defined as:
Finally, the estimation of SG and SI parameters of the model was performed using the software (MINMOD) kindly donated by Richard N. Bergman, MD, PhD.
Ultrasonographic Measurements
Echocardiographic examination were performed and interpreted by the same cardiologist, who was unaware of the patient's BP and IVGTT results. The studies were obtained with the patient lying in a modified left lateral decubitus position with the head angled at 30°from the horizontal to obtain parasternal and apical views. Recordings were made with an Acuson Aspen echograph (Acuson Corp., Mountain View, CA).
M-mode studies of the left ventricle were obtained under cross-sectional control from the parasternal long axis view. The LV measurements were obtained at enddiastole. Measurement criteria were those of the American Society of Echocardiography. 18 The LV measurements included: interventricular septal thickness (IVST), posterior LV wall thickness (PWT), and LV internal dimension (LVID). The LV wall thickness (LVWT) was calculated with the following formula: LVWT ϭ PWT ϩ IVST. The LVM was calculated from the Penn convention measurements with the following formula: LVM (in grams) ϭ 1.04 3 ] Ϫ 13.6, and was indexed by body surface area. Individual measurements reported are derived according to the American Society of Echocardiography convention. Cut-off points for LVH were Ͼ134 g/m 2 for men and Ͼ110 g/m 2 for women. 19, 20 The LV mass was also indexed by height (in meters) and raised to the 2.7 power (LVM/ht 2.7 ). Pulsed Doppler recordings of transmitral flow velocities were performed from the apical four-chamber view, with sample volume placed at the level of mitral leaflet tips. The following measurements were determined: the early filling phase peak transmitral flow velocity (peak E), the late diastolic filling phase peak transmitral flow velocity (peak A), their ratio (E:A), velocity time integral of E wave (VTIE), velocity time integral of A wave (VTIA), and their ratio (VTIE:VTIA).
Statistical Analysis
All data are expressed as the mean Ϯ SD. For comparison of means, the Student t test was used for all normally distributed variables and the Mann-Whitney test for nonnormally distributed variables. Previously, normality of distribution was studied using the Kolmogorow-Smirnoff test. Fisher's exact test was used to study the prevalence of LVH in subjects situated in the lowest quartile of the distribution of the SG parameter. The relationship among the variables was analyzed by single regression analysis. An additional multiple regression analysis was performed among variables of the minimal model and other variables known to cause LVH. Finally, a binary logistic regression analysis (Wald's method) was performed to establish which variables were independently related to LVH. All statistical analyses were performed using the software SPSS version 10.0 (SPSS Inc., Chicago, IL). A value of P Ͻ .05 was considered to be significant
Results
There were 22 subjects (61.1%) with diastolic dysfunction, defined as a ratio between E and A waves Ͻ1. However, only seven patients (19.4%) had LVH, defined as LVM index Ͼ134 g/m 2 in men and Ͼ110 g/m 2 in women. 21 As shown in Table 1 , there were no significant differences regarding age, sex, body mass index, waist-to-hip ratio, or BP between patients with or without LVH.
As listed in Table 2 , subjects with LVH had significantly lower values of SG and GEZI and also had higher fasting glucose concentrations than those without LVH. However, the SI parameter was similar in both groups. Figures 1, 2 , and 3 show a strong relationship among SG, GEZI or fasting glucose, and LVM (Figs. 1A, 2A, 3A) or LVM index (Figs. 1B, 2B, 3B ). There was also a significant relationship of LVM/ht 2.7 with SG (r ϭ 049, P Ͻ .005), GEZI (r ϭ 0.51, P Ͻ .005), and fasting glucose (r ϭ 0.49, P Ͻ .005). An additional multivariate analysis was performed that included the following variables, entered in order and evaluated for independent contribution to LVM index: SG, mean 24-h systolic BP, mean 24-h diastolic BP, age, and body mass index. In this analysis, only SG remained independently related to LVM (F ϭ 6.870, P Ͻ .0001) or LVM index (F ϭ 5.991, P Ͻ .001).
As expressed in Table 3 , SG, GEZI, and fasting glucose were significantly related to all of the studied parameters, measuring both hypertrophy and diastolic function. However, SI parameter was significantly related to parameters measuring diastolic function but not ventricular mass.
When the subjects were classified according to the distribution by quartile of the distribution of SG parameter, we observed that data for six of seven patients with LVH were distributed below the lowest quartile of this distribution, whereas only two of 29 without LVH were distributed below this quartile (odds ratio ϭ 81.0, CI ϭ 4.8 to 3848.9, P Ͻ .0001). Table 4 shows that subjects below the lowest quartile of the distribution of SG had more LVH and worse diastolic function than those in the three upper quartiles. Finally, a multiple binary logistic regression analysis (Wald's method) shows that SG (P Ͻ .05), GEZI (P Ͻ .05), and fasting glucose (P Ͻ .05) were predictors of the presence of LVH, independently of body mass index, age, heart rate, and mean 24-h systolic or diastolic BP.
Discussion
In this study, we have assessed the IVGTT and minimal model analysis in a group of nonobese, glucose-tolerant, untreated patients with recently diagnosed stage I essential hypertension or high-normal BP. Left ventricular hypertrophy, defined according to the criteria of Deveraux et al, 21 was present in only seven patients (19.4%), whereas diastolic dysfunction was observed in 61.1% of subjects. This is in agreement with a recent study indicating that diastolic dysfunction precedes LVH, 22 and is concordant with the expected value in a sample of subjects with stage I or high-normal BP.
In these subjects, we have observed that there is a significant relation among fasting glucose as well as, SG, and GEZI parameters of the IVGTT and all the studied echocardiographic parameters measuring mass (Figs. 1 to 3 and Table 3 ). Consistently, six of seven patients with LVH were distributed below the lowest quartile of the distribution of SG parameter, whereas only two of 29 without LVH were distributed below this quartile (P Ͻ .0001). In agreement with this, the mean value of SG was lower in subjects with LVH than in those without (Tables  3 and 4) . This relationship is probably not due to chance, as there were no statistically significant differences between patients with and without LVH with regard to other factor influencing ventricular mass (Table 1) . Moreover, in a multivariate binary logistic regression analysis, only fasting glucose, SG, and GEZI were independent predictors of LVH.
To our knowledge, the relationship among SG or GEZI parameters of the IVGTT and LVM in essential hypertension has not been studied to date. Avignon et al 23 studied the influence of lean body mass on LVM in obese individuals and observed a very significant relationship between fasting plasma glucose and LVM despite the fact that the subjects studied were glucose tolerant (n ϭ 24, r ϭ 0.62, P Ͻ .001). Watanabe et al 24 also found a positive and significant relationship between LVM index and hemoglobin A 1c in patients with essential hypertension. Moreover, hypertensive individuals with diabetes have been found to have higher LVM than nondiabetic hypertensive patients with similar BP. 21 Finally, in a prospective study, it was described that improvement in glycemic 
FIG. 3. Relationship between fasting glucose and (A) left ventricular mass (LVM) or (B) left ventricular mass index (LVM index).
control contributed to regression of LVH in hypertensive patients with type 2 diabetes, and that these changes occurred independently of variation in BP. 20 In vitro, glucose itself can induce proliferation and hypertrophy of vascular smooth cell, possibly through the activation of the phospholipase D and protein kinase C pathways. 25 In this respect, the aldose reductase inhibitor eparelstat prevents a glucose-induced hyperproliferation and hypertrophy of cultured rat vascular cells, possibly through protein kinase C suppression. 26 It has been shown that transgenic mice overexpressing protein kinase C ␤ isoform in the myocardium developed cardiac hypertrophy. 27 More recently, other proteins such as mitogenactivated protein kinases, nuclear transcription factors, Jannus family of activated kinases, and signal traducers of activators of transcription have been related to this glucose-activated hyperproliferation. 28 Finally, Barbagallo et al 29 have demonstrated that glucose increases intracellular calcium, and that this increase directly stimulates vascular proliferation and hypertrophy in vitro. Moreover, these investigators 30 have also observed that in diabetic patients, both fasting glucose and glucose response to an oral glucose tolerance test (another possible measure of glucose effectiveness), but not insulin response, is related to LVM.
In conclusion, there is varied evidence from both clinical and basic studies to suggest that glucose per se, independently of insulin, may contribute to the development of cardiovascular hypertrophy.
In our study, we did not observe any significant relationship between SI index and parameters measuring LVM. However, we found a significant relationship between SI and parameters measuring diastolic function ( Table 3 ). This might signify that SI parameter is more closely related to myocardial fibrosis than to hypertrophy. It is also possible that a relationship between SI and LVM might exist if the subjects studied had severe hypertension with obesity and glucose intolerance. In this case, it could be suggested that SG and GEZI parameters of the IVGTT might be more sensitive than SI for early detection of hypertensive cardiomyopathy. In this respect, it has been reported that SG and GEZI, but not SI, are reduced in glucose-tolerant offspring of individuals with non-insulindependent diabetes mellitus, and therefore that glucose resistance precedes insulin resistance in such subjects. 31 Nonetheless, our study design does not allow us to establish whether SG or GEZI is a more sensitive parameter than SI for early detection of hypertensive cardiomyopathy, and therefore further studies are needed to determine this.
Our report of the absence of a relationship between SI LVWT ϭ left ventricular wall thickness; PWT ϭ posterior wall thickness; SWT ϭ septal wall thickness; VTIE:VTIA ϭ velocity time integral of E and A waves ratio; other abbreviations as in Table 2 .
Values are mean Ϯ SD. and LVM is in agreement with a recent report of Galvan et al 32 using the insulin clamp technique. However, Phillips et al, 33 using a design similar to ours, reported some discrepancy with our data. These investigators studied a sample of 29 nonobese subjects with untreated mild or borderline essential hypertension, and observed a significant relationship (P ϭ .02) between SI index and LVM index. However, the relationship of LVM index with fasting insulin or with insulin area under the curve was not significant. The investigators recognized that one limitation of their study was the ethnic heterogeneity of the studied subjects. In this regard, it is known that the relationship between insulin resistance and BP is variable among different ethnic groups. 4 Moreover, a relationship between LVM index and the SI parameter of the IVGTT was not found by Avignon et al 23 in normotensive normoglycemic obese women. Unfortunately, neither Phillips et al 33 nor Avignon et al 23 calculated the SG and GEZI parameter of the IVGTT.
In summary, we selected a population of subjects who may be representative of an early stage of human hypertension with a low prevalence of insulin resistance. These were nonobese, nondiabetic, and untreated individuals with recently diagnosed mild or borderline essential hypertension. In this situation we found a strong relationship among glucose effectiveness or glucose effectiveness at zero insulin and all of the studied parameters measuring LVM. We hypothesized that "glucose resistance" may be present even in the absence (or before the appearance) of the so-called insulin resistance syndrome, and that this glucose resistance is also independently related to the LVH observed in patients with essential hypertension.
